ORIGINAL ARTICLE

Supplemental Effect of Zinc Oxide Nanoparticles and Prangos ferulacea Butanol Extract on Blood Glucose of Diabetic Wistar Rats

Hamid Dadar1, Reza Bzorgyan2, Freshteh Rahdan3, Elahe Piraei3, Yadollah Edalatpanah4

1Deptartment of Biochemistry, Shiraz Branch, Islamic Azad University, Shiraz, Iran
2Deptartment of Microbiology, Shiraz Branch, Islamic Azad University Shiraz, Iran
3Deptartment of Biotechnology, Dehdasht Branch, Islamic Azad University, Dehdasht, Iran
4Deptartment of Biochemistry, Dehdasht Branch, Islamic Azad University, Dehdasht, Iran

(Received: 2 January 2017 Accepted: 13 March 2017)

ABSTRACT: Diabetes mellitus is one of the most common diseases affecting the endocrine system. The prevalence of diabetes mellitus will be increasing in the human population. It is a metabolic disease characterized by chronic escalation of blood glucose and disrupted metabolism of carbohydrates, fats and proteins. This was an experimental study conducted on 40 male Wistar rats. Diabetes was induced in the animals through Streptozotocin (STZ). After three days, blood glucose levels were measured. The rats were diagnosed with diabetes when blood glucose was more than 250. The data were analyzed through SPSS 21. Moreover, the independent t-test was used to examine the relationship between variables. Results of statistical analysis in relation to body weight of rats showed that there was a significant relationship between all groups at P<0.05 except for diabetic group and diabetic group by Prangos ferulacea butanol extract as well as diabetic group by P. ferulacea butanol extract and diabetic groups by P. ferulacea butanol extract and zinc oxide nanoparticles. Concerning the glucose levels, there was a significant relationship between all groups at P<0.05. When applied as a supplement, zinc oxide nanoparticles and P. ferulacea butanol extract can have anti-diabetic properties, curtailing blood glucose, revealing that nanoparticles can be used in the future as a treatment for diabetes.

INTRODUCTION

Diabetes mellitus is one of the most common diseases affecting the endocrine system [1]. The prevalence of diabetes mellitus is increasing in the human population [2]. It is a metabolic disease characterized by chronic escalation of blood glucose and disrupted metabolism of carbohydrates, fats, and proteins [3].
Diabetes is accompanied with long-term complications such as retinopathy, nephropathy, neuropathy and cardiovascular diseases. More than 3.6% of the world’s populations are currently suffering from diabetes mellitus. In the process of diabetes, long episodes of hyperglycemia can lead to production of free radicals, especially ROS [4]. It represents the oxidation of glucose and protein glycation, where the undesirable conditions in all tissues can impair the balance between ROS production and cell defense mechanism [5]. This imbalance leads to cell damage and changes in the cell function and tissue damage, especially pancreas [6].

There is currently a great interest of medical and food industry in the detection of antioxidant compounds with pharmacological potential without any side effects or at least with minimal side effects [7]. Due to the high cost and side effects of chemical drugs today, it has become a top priority to study plants used in traditional medicine to achieve further progress in medical sciences. Herbal remedies are natural substances with lower risk of side effects. Many of these herbs provide a rich source of natural antioxidants that can curtail the side effects of oxidants and some diseases. Belonging to genus Apiaceae, Prangos ferulacea grows across different areas of Iran including the Alborz slopes, Azerbaijan, Kurdistan, Kerman, and Fars. Many of its species can be found in India, Anatolia, Central Asia, Iran and the Pacific [8].

P. ferulacea is a valuable herb used in traditional medicine for the treatment of many diseases. Numerous experimental studies have proven its therapeutic properties. In traditional medicine, Prangos ferulacea has been applied as a carminative, laxative, stomach tonic, relieving the nervous system, anti-inflammatory, anti-virus, anti-parasitic, antifungal and anti-bacteria substance [9]. This plant grows in Apr and develops all through May. Afterward, it initiates the reproductive stage and produces its fruit in late May. The seed ripen in early July and at the same time; the plant begins to wilt away completely. At the beginning of Aug, the plant undergoes a dormant phase and there are usually no remains on the ground. The green stems of P. ferulacea are edible. In late Apr and early May, this plant grows on. It can be used as food after drying. The leaves of P. ferulacea are applied for treatment of digestive diseases, without exposing to toxicity [10].

Phytochemical studies have isolated and identified a variety of coumarins, alkaloids, flavonoids and terpenoids in prangos species. This herb is rich in antioxidants [11]. Phytochemical studies indicated the presence of coumarins, alkaloids, flavonoids and terpenoids in the plant. Furthermore, some important compounds such as Emily feron, frandol, frolden, prangon and pentylcoumarin have been identified at the root of P. ferulacea. Antioxidant compounds in P. ferulacea are important for reduction of oxidative stress [12].

In recent years, however, the structure of inorganic nanoparticles has been the subject of much speculation in terms of physical, chemical and biological properties. Moreover, the high potential of nanomaterials in biology and pharmacology has attracted many researchers. There are several applications of nanomaterials such as treatment of HIV [13]. The nanoparticles can be used in drug delivery applications, production of high-quality microscopic images, treatment of cancer and diseases [14]. Other applications of nanotechnology can be found in drug deliver to treat cancer-involving liposomes [15]. In this regard, consumption of P. ferulacea hydroalcoholic extract in the treated diabetic group decreased serum creatinine and urea nitrogen levels compared to the control group Antioxidant properties of P. ferulacea can strengthen the antioxidant system and resistance against oxidative stress in rats, thus curtailing the risk of kidney damage. Urea and creatinine rise by increasing renal function in diabetic rats [16].
The anti-diabetic properties of *P. ferulacea* were examined for the first time, revealing that diabetic rats treated with the hydroalcoholic extract of *P. ferulacea* roots significantly reduced blood glucose, total cholesterol, triglyceride and glycosylated hemoglobin and significantly increased HDL levels and adjusting the white blood cells (WBC) to normal level [17].

*P. ferulacea* extract significantly improved the tissue lesions in kidney, liver and pancreas and minimized most unfavorable changes in tissues, including necrotic foci, tissue atrophy, increased lymphocyte attack and glomerulonephritis renal lesions in some areas largely similar to the healthy subjects, mainly due to an increase in body weight of rats under treatment [18].

In a study on the effect of *P. ferulacea* hydroalcoholic extract on blood indices of kidney and liver functions among male diabetic rats showed that levels of blood glucose, aspartate amino transferase, alanine amino transferase and creatinine in groups treated with *P. ferulacea* hydroalcoholic extract significantly decreased compared to the diabetic group. Levels of alkaline phosphatase, urea, urea nitrogen and albumin decreased, but not significantly. Concerning the anti-diabetic effect of ZnO nanoparticles, there has not been any specific research [19].

In another study, zinc nano-oxide and its composition with nano-silver could induce cell death in cancer cells at micromolar concentrations of melanoma [20]. The acute toxicity of zinc nano-oxide on serum biochemical liver function in white rats was examined, where the results indicated that zinc nano-oxide can be toxic on liver and should be consumed with caution [21].

The aim of this study was to evaluate the supplemental effect of zinc oxide nanoparticles with *P. ferulacea* extract on blood glucose levels in diabetic Wistar rats.

**MATERIALS AND METHODS**

This was an experimental study where *P. ferulacea* was harvested in May 2014 from Jokar in Boyer Ahmad, located 120 km from Yasouj, Iran. In order to prepare two separate hydro-alcoholic extracts, the roots of the plant were individually and the stems and green leaves together were harvested at a weight ratio of 1:1. The samples were identified by professors of botany at University of Yasouj. Then, they were labeled and stored in the herbarium. The samples were then dried and crushed into powder in the mill. At the next stage, 100 gr of powdered roots, as well as 100 gr of powder mixture stems and leaves separately were poured into 1-liter flasks, to which 96% ethanol was added, so that it covered the surface of the powder. After 24 h, the solutions were filtered. Next, 75% alcohol was added to the remaining pulp. After 24 h, the solutions were filtered again and then concentrated by vacuum distillation at 50°C; 70 rpm was to one-third of the original volume. Solutions obtained from the last step in the autoclave (IranTolid medical equipment) were dried at 40°C under sterile conditions. In this procedure, the dry powder extracts were prepared after a few days and were kept at 4°C [22]. The Zinc oxide nanoparticles were supplied by TECONAN, Spain (diameter 20-25 nm). Purity of zinc oxide nanoparticles was more than 99.98%. Zinc oxide nanoparticles were dissolved in double sterile distilled water and sonicated to be scattered forming the same colloidal suspension. All tests involved a freshly prepared colloidal suspension system. Then, the solution of 8 mM zinc oxide nanoparticles was applied to examine the anti-diabetic effects [23].

In this experimental study, 40 Wistar rats in the weight range of 250 to 300 gr were supplied by an Animal House at Yasuj University of Medical Sciences. Animal were exposed to a cycle of 12 h of light and 12 h of dark at 20 degrees centigrade and relative humidity of 25 to 30 percent, along with a standard diet of pellets and municipal water. In order to achieve a compromise with the environment, all the tests were performed after at least 10 d since the establishment of animals in the nest.
Ethics of research was exercised regarding with minimal harassment. Laboratory animals were studied in accordance with the guidelines approved by the Ethical Committee of Faculty of the Medical Sciences of Yasouj and after a period of 30 days were anesthetized by ether for pain relief.

In this study, 40 rats were divided randomly into 5 groups of 8 each, including:
1- Control group receiving normal saline only during the experiment.
2- Streptozotocin-induced diabetic control group only receiving normal saline.
3- Streptozotocin-induced diabetic rats receiving 100 mg/kg of *P. ferulacea* extract.
4- Streptozotocin-induced diabetic rats receiving 8 mm of zinc nano-oxide solution.
5- Streptozotocin-induced diabetic rats received zinc oxide nanoparticles and *P. ferulacea* butanol extract as a supplement [12].

After 12 h of fasting, the experimental model of diabetes mellitus type 1 was employed in rats with a single intraperitoneal injection of streptozotocin at 120 mg per kg of body weight. Symptoms of diabetes included polydipsia, urination and weight loss after 5 d. The blood glucose levels of diabetic rats are ensured through collecting blood samples from tails and direct lancing of the tail. The blood samples were poured into test tubes and then transferred to the laboratory for biochemical tests. The data were analyzed through SPSS 19 (Chicago, IL, USA). Moreover, the independent t-test was used to examine the relationship between the groups.

**RESULTS**

**Weight of the experimental rats**

In relation to the weight of the rats, Figure 1 indicates the diabetic group was 263.4 and 320.7 before and after the test, respectively. The weights for the diabetic group together with intake of zinc oxide nanoparticles before and after were 261.8 and 304.9, respectively. Streptozotocin-induced diabetic rats experienced higher body weight. For diabetics receiving *P. ferulacea*, the weights before and after the test were 260.6 and 289.8, respectively. As for the diabetics receiving ZnO nanoparticles and *P. ferulacea*, the weights before and after the test were 260.1 and 290.25, respectively.

![Figure 1. Weight levels in experimental rats](image-url)
Comparison of the weight of diabetic group and zinc oxide nanoparticles diabetic group showed a significant difference at \( P<0.05 \). Comparison of nanoparticle zinc oxide diabetic group and \( P. \) ferulacea butanol extract + zinc oxide nanoparticles diabetic group showed a significant difference at \( P<0.05 \). Therefore, zinc oxide nanoparticles with \( P. \) ferulacea can reduce the weight of diabetic rats. Comparison of the weight of diabetic group and \( P. \) ferulacea diabetic group showed no significant difference at \( P<0.05 \). Comparison of Prangos ferulacea diabetic group and \( P. \) ferulacea butanol extract + zinc oxide nanoparticles diabetic group showed no significant difference at \( P<0.05 \). Therefore, \( P. \) ferulacea cannot reduce the weight of diabetic rats. However, it can be a factor in reducing body weight (Table 1).

<table>
<thead>
<tr>
<th>Groups</th>
<th>Significance</th>
<th>( T )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetics and ZnO NP diabetic group</td>
<td>0.04</td>
<td>4.16</td>
</tr>
<tr>
<td>Diabetic group and ( P. ) ferulacea butanol extract diabetic group</td>
<td>0.232</td>
<td>1.3</td>
</tr>
<tr>
<td>Diabetic group and ( P. ) ferulacea butanol extract and zinc oxide nanoparticles diabetic group</td>
<td>0.0</td>
<td>7.6</td>
</tr>
<tr>
<td>( P. ) ferulacea butanol extract diabetic group and ( P. ) ferulacea butanol extract and zinc oxide nanoparticles diabetic group</td>
<td>0.984</td>
<td>0.021</td>
</tr>
<tr>
<td>ZnO NP diabetic group and ( P. ) ferulacea butanol extract and zinc oxide nanoparticles diabetic group</td>
<td>0.0</td>
<td>-6.7</td>
</tr>
</tbody>
</table>

**Glucose level of the experimental rats**

In relation to blood glucose of tested rats, Figure 2 indicated that glucose levels in the control before and after the test were 101.6 and 100, respectively, showing no significant difference between the rats. As for the diabetic control group, the mean glucose levels before and after the test was 104.9 and 186.25, respectively. For diabetic + zinc oxide nanoparticles group before and after the test, the mean glucose levels were 95.6 and 141.4, respectively. For diabetic + \( P. \) ferulacea group before and after the test, the mean glucose levels were 101 and 149.3, respectively. For diabetic + zinc oxide nanoparticles + \( P. \) ferulacea group, the mean glucose levels before and after the test was 96.6 and 129.1, respectively.
Comparison of the glucose level of diabetic group and zinc oxide nanoparticles diabetic group showed a significant difference at \( P<0.05 \). Comparison of nanoparticle zinc oxide diabetic group and \( P. \) ferulacea butanol extract + zinc oxide nanoparticles diabetic group showed a significant difference at \( P<0.05 \). Therefore, zinc oxide nanoparticles can reduce the glucose level in diabetic rats. Comparison of the blood glucose of diabetic group and \( P. \) ferulacea diabetic group showed a significant difference at \( P<0.05 \). Comparison of \( P. \) ferulacea diabetic group and \( P. \) ferulacea butanol extract + zinc oxide nanoparticles diabetic group showed a significant difference at \( P<0.05 \). Therefore, \( P. \) ferulacea can reduce the blood glucose of diabetic rats. Hence, \( P. \) ferulacea and zinc nano-oxide can reduce blood glucose in diabetic rats (Table 2).

Table 2. The findings of the independent t-test analysis in relation to the glucose level of the rats under study.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Significance level</th>
<th>T</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetics and ZnO NP diabetic group</td>
<td>0.00</td>
<td>10.6</td>
</tr>
<tr>
<td>Diabetic group and ( P. ) ferulacea butanol extract diabetic group</td>
<td>0.006</td>
<td>-3.93</td>
</tr>
<tr>
<td>Diabetic group and ( P. ) ferulacea butanol extract and zinc oxide nanoparticles diabetic group</td>
<td>0.00</td>
<td>30.2</td>
</tr>
<tr>
<td>( P. ) ferulacea butanol extract diabetic group and ( Prangos ) ferulacea butanol extract and zinc oxide nanoparticles diabetic group</td>
<td>0.00</td>
<td>-7.06</td>
</tr>
<tr>
<td>ZnO NP diabetic group and ( P. ) ferulacea butanol extract and zinc oxide nanoparticles diabetic group</td>
<td>0.01</td>
<td>-5.3</td>
</tr>
</tbody>
</table>

DISCUSSION

In the twenty-first century, diabetes is known as one of the most common diseases in the world and Iran [6]. There is currently no cure for diabetes and only discovered drugs can improve the disease and increase the chances of survival [7]. Nowadays, herbs are widely used to treat diseases. Moreover, a broad range of studies has been conducted in developed and the developing countries on the importance of this plant in the treatment of diseases, particularly diabetes [8]. \( P. \) ferulacea is known as one of the herbs used in the treatment of diseases owing to its powerful antioxidant compounds [9]. Twenty-first centuries can be called the century of nanoparticles, found wide applications in various fields of nanotechnology. The advanced countries have now resorted to the use of nanoparticles for the treatment of refractory diseases [24].

In relation to the mean weight of diabetic rats, the pre-test weight of 263.4 increased to 320.7 after the test in streptozotocin-induced diabetic rats. As for the ZnO nanoparticles diabetic group, the results indicated that the pre-test mean weight of 261.8 increased to 304.9 in the post-test phase, which managed to curtail the mean weight as compared to the nanoparticles diabetic group. In the diabetic group with \( P. \) ferulacea butanol extract, the pre-test mean weight of 260.6 increased to 289.8 in the post-test phase, which managed to curtail the mean weight as compared to the \( P. \) ferulacea butanol extract diabetic group. Moreover, the \( P. \) ferulacea butanol extract was more successful than zinc oxide nanoparticles in reducing the weight of rats. As for the \( P. \) ferulacea butanol extract diabetic group, the pre-test means weight of 260.1 increased to 304.9 in the post-test phase, which
managed to curtail the mean weight as compared to the
P. ferulacea butanol extract diabetic group. Compared
with zinc oxide nanoparticles diabetic group, the P.
ferulacea butanol extract and zinc oxide nanoparticles
diabetic group managed effectively to reduce body
weight of rats. Compared to the P. ferulacea butanol
extract diabetic group, however, it failed to reduce body
weight of rats.

In relation to the glucose level of diabetic rats, the pre-
test glucose of 104.9 increased to 186.25 after the test in
streptozotocin-induced diabetic rats. As for the ZnO
nanoparticles diabetic group, the pre-test glucose of 95.6
increased to 141.4 in the post-test phase, which man-
aged to curtail the glucose as compared to the nanoparti-
cles diabetic group.

In the diabetic group with P. ferulacea butanol extract,
the pre-test glucose of 101 increased to 149.3 in the
post-test phase, which managed to curtail the glucose as
compared to the P. ferulacea butanol extract diabetic
group. Moreover, the P. ferulacea butanol extract was
less successful than zinc oxide nanoparticles in reducing
the glucose level of rats. As for the P. ferulacea butanol
extract diabetic group, the pre-test glucose of 96.6 in-
creased to 129.1 in the post-test phase, which managed
to curtail the glucose as compared to the P. ferulacea
butanol extract diabetic group. Compared with zinc ox-
ide nanoparticles diabetic group and P. ferulacea buta-
ol extract diabetic, the P. ferulacea butanol extract and
zinc oxide nanoparticles diabetic group managed effec-
tively to curtail the glucose level in rats.

CONCLUSIONS

The of zinc oxide nanoparticle as additive with P. feru-
lacea extract has been effective in blood glucose and
weight reducing of diabetic rats. Nanoparticles used in
combination with medicinal plants against diabetes.

ACKNOWLEDGEMENTS

Thank and appreciate of research assistant of Islamic
Azad University of Dehdasht for collaboration with this
project. The authors declare that there is no conflict of
interest.

REFERENCES

1. Bogunia-Kubik K., Sugisaka M., 2002. From molecu-
lar biology to nanotechnology and nanomedicine. Bio-
systems. 65, 123–138.

2. Gref R., Luck M., Quellec P., Marchand M., Del-
lacherie E., Harnisch S., Blunk T., Muller, R. H., 2000.
“Stealth” corona-core nanoparticles surface modified by
polyethylene glycol (PEG): influences of the corona
(PEG chain length and surface density) and of the core
composition on phagocytic uptake and plasma protein


4. Soltani Kh., Kafash Farkhad N., Farokhi F., Tog-
mechi A., 2012. Effects of hydro-alcoholic extract of
Prangos ferulacea L. Lindle on histopathology of pa-
creas and diabetes treatment in STZ- induced diabetic

take of dextrancoated monocrystalline iron oxides in
7, 1140–1145.

6. Jadidoleslame M., SHahraki M., Abbasnejad M.,
2011. The survey of Aleovera aqueous extra and
inhibinclamid interaction on blood glucose, LFT and
lipids diabetic induced male rats by streptozotocin. Raf-

7. Srivastava Y., Venkatakrishnan-Bhatt H., Verma Y.,
2003. Antidiabetic and adaptogenic properties of
Momordica charantia extract: an experimental and clin-

8. Coruh N., Celep A.G.S., Ozgokce F., 2007. Antioxi-
dant properties of Prangos ferulacea L. Lindl., Chaero-
phyllum macropodum Boiss. and Heracleum persicum Desf. From Apiaceae family used as food in Eastern Anatolia and their inhibitory effects on glutathione-S-transferase. Food Chem. 100(3), 1237-42.


